| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69ece09bafee7e0c49d1f7951a3faa2c |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2018-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1904850377034b0d03f1e25333c30ee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00aa32dbcc5d99b4873617eb5598eb39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1dd7f7d007fb60202211182ecacc6ba |
| publicationDate |
2020-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-202021625-A |
| titleOfInvention |
Methods of using anti-cd79b immunoconjugates |
| abstract |
Provided herein are methods of treating B-cell proliferative disorders (such as Diffuse Large B-Cell Lymphoma "DLBCL") using immunoconjugates comprising anti-CD79b antibodies in combination with an alkylating agent (such as bendamustine) and an anti-CD20 antibody (such as rituximab). |
| priorityDate |
2018-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |